comparemela.com

Latest Breaking News On - Cogent biosciences inc - Page 12 : comparemela.com

15 Small-Cap Stocks with High Potential

In this article, we will take a look at the 15 small-cap stocks with high potential. To skip our analysis of the latest trends, and market activity, you can go directly to see the 5 Small-Cap Stocks with High Potential. Nearly 9,500 stocks trade on major U.S. stock exchanges with nearly half of them having […]

Spain
Italy
Cambridge
Cambridgeshire
United-kingdom
France
Waltham
Massachusetts
United-states
Boston
Switzerland
American

15 Small-Cap Stocks with High Potential - Insider Monkey

In this article, we will take a look at the 15 small-cap stocks with high potential.

Cambridge
Cambridgeshire
United-kingdom
Spain
Italy
Boston
Massachusetts
United-states
France
Switzerland
Waltham
American

Cogent Biosciences (NASDAQ:COGT) Earns Neutral Rating from Wedbush

Cogent Biosciences (NASDAQ:COGT – Get Free Report)‘s stock had its “neutral” rating reiterated by analysts at Wedbush in a research note issued on Tuesday, RTT News reports. A number of other brokerages also recently commented on COGT. HC Wainwright dropped their target price on shares of Cogent Biosciences from $27.00 to $13.00 and set a […]

Needham-company
Renaissance-technologies
Metlife-investment-management
Jpmorgan-chase-co
Cogent-biosciences-inc
Dimensional-fund-advisors
Cogent-biosciences
Get-free-report
Life-investment-management
Fund-advisors
Street-corp

Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San-francisco
California
United-states
Andrew-robbins
Christi-waarichsenior
Cogent-biosciences-inc
Cogent-research-team
Twitter
Linkedin
Nasdaq
Chief-executive-officer
Healthcare-conference

Top Midday Decliners

Cogent Biosciences said Monday four patients reported related serious adverse events in the first of a two-part phase 2 trial of bezuclastinib in patients with advanced systemic mastocytosis..

Cogent-biosciences-inc
Cogent-biosciences
Markets

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.